Literature DB >> 10892906

Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation.

R C King1, O A Binns, F Rodriguez, R C Kanithanon, T M Daniel, W D Spotnitz, C G Tribble, I L Kron.   

Abstract

BACKGROUND: Reperfusion injury after pulmonary transplantation can contribute significantly to postoperative pulmonary dysfunction. We hypothesized that posttransplantation reperfusion injury would result in an increase in both in-hospital mortality and morbidity. We also hypothesized that the incidence of reperfusion injury would be dependent upon the cause of recipient lung disease and the interval of donor allograft ischemia.
METHODS: We performed a retrospective study of all lung transplant recipients at our institution from June 1990 until June 1998. One hundred patients received 120 organs during this time period. We compared two groups of patients in this study: those experiencing a significant reperfusion injury (22%) and those who did not (78%).
RESULTS: In-hospital mortality was significantly greater in patients experiencing reperfusion injury (40.9% versus 11.7%, p < 0.02). Posttransplantation reperfusion injury also resulted in prolonged ventilation (393.5 versus 56.8 hours, p < 0.001) and an increased length of stay in both the intensive care unit (22.2 versus 10.5 days, p < 0.01) and in the hospital (48.8 versus 25.6 days, p < 0.03). The incidence of reperfusion injury could not be attributed to length of donor organ ischemia (221.5 versus 252.9 minutes, p < 0.20). The clinical impact of reperfusion injury was significantly greater in patients undergoing transplantation for preexisting pulmonary hypertension (6/14) than those with chronic obstructive pulmonary disease or emphysema alone (6/54) (42.9% versus 11.1%, p < 0.012).
CONCLUSIONS: Clinically significant pulmonary reperfusion injury increased in-hospital mortality and morbidity resulting in prolonged ventilation, length of stay in the intensive care unit, and cost of hospitalization. The incidence of reperfusion injury was not dependent upon the duration of donor organ ischemia but increased with the presence of preoperative pulmonary hypertension. These findings suggest that recipient pathophysiology and donor allograft quality may play important roles in determining the incidence of reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10892906     DOI: 10.1016/s0003-4975(00)01425-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  66 in total

1.  Five-year update on the mouse model of orthotopic lung transplantation: Scientific uses, tricks of the trade, and tips for success.

Authors:  Xue Lin; Wenjun Li; Jiaming Lai; Mikio Okazaki; Seiichiro Sugimoto; Sumiharu Yamamoto; Xingan Wang; Andrew E Gelman; Daniel Kreisel; Alexander Sasha Krupnick
Journal:  J Thorac Dis       Date:  2012-06-01       Impact factor: 2.895

Review 2.  Lung transplantation: opportunities for research and clinical advancement.

Authors:  David S Wilkes; Thomas M Egan; Herbert Y Reynolds
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

3.  Integrin alphavbeta5 regulates lung vascular permeability and pulmonary endothelial barrier function.

Authors:  George Su; Maki Hodnett; Nanyan Wu; Amha Atakilit; Cynthia Kosinski; Mika Godzich; Xiao Zhu Huang; Jiyeun K Kim; James A Frank; Michael A Matthay; Dean Sheppard; Jean-François Pittet
Journal:  Am J Respir Cell Mol Biol       Date:  2006-11-01       Impact factor: 6.914

4.  Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival.

Authors:  Chad A Newton; Julia Kozlitina; Jefferson R Lines; Vaidehi Kaza; Fernando Torres; Christine Kim Garcia
Journal:  J Heart Lung Transplant       Date:  2017-02-04       Impact factor: 10.247

Review 5.  Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Authors:  Liliane Michalik; Walter Wahli
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 6.  Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.

Authors:  Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-13       Impact factor: 3.000

7.  Minocycline and doxycycline, but not other tetracycline-derived compounds, protect liver cells from chemical hypoxia and ischemia/reperfusion injury by inhibition of the mitochondrial calcium uniporter.

Authors:  Justin Schwartz; Ekhson Holmuhamedov; Xun Zhang; Gregory L Lovelace; Charles D Smith; John J Lemasters
Journal:  Toxicol Appl Pharmacol       Date:  2013-09-05       Impact factor: 4.219

8.  Direct hemoperfusion with a polymyxin B-immobilized cartridge in intestinal warm ischemia reperfusion.

Authors:  Hiroaki Sato; Kiyohiro Oshima; Kazuhisa Arakawa; Katsumi Kobayashi; Hodaka Yamazaki; Yujin Suto; Izumi Takeyoshi
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

9.  Differential toll-like receptor activation in lung ischemia reperfusion injury.

Authors:  Patrick Phelan; Heather E Merry; Billanna Hwang; Michael S Mulligan
Journal:  J Thorac Cardiovasc Surg       Date:  2015-02-28       Impact factor: 5.209

10.  Hemoperfusion with polymyxin B-immobilized fiber column improves liver function after ischemia-reperfusion injury.

Authors:  Hiroaki Sato; Kiyohiro Oshima; Katsumi Kobayashi; Hodaka Yamazaki; Yujin Suto; Izumi Takeyoshi
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.